What Дитилин treats: Main Uses and Benefits

Дитилин (succinylcholine chloride) is an agent relevant in clinical settings that involve acute or unstable symptom patterns. Its main therapeutic domain is to assist with temporary skeletal muscle relaxation (paralysis), which is commonly used across conditions presenting with acute episodes.

The medication's primary use is as an adjunct to general anesthesia to facilitate essential procedures, thereby assisting with maintaining functional stability during critical medical interventions. Its main indications are to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.

By inducing temporary flaccid paralysis, the medication helps address symptom clusters that may become intense or disruptive, specifically involuntary muscle contractions, contributing to the support needed for critical interventions. The benefit offered supports the patient during difficult episodes by easing distress and assists with maintaining functional stability. It is often applied in scenarios where short-term symptomatic assistance is needed.

Quick Fact: Relief for Involuntary Muscle Contractions

Eligibility Map: Who Can and Cannot Use Дитилин (Succinylcholine Chloride) — Official Regulatory Information

The use of Дитилин is strictly governed by regulatory status, primarily due to the risk of life-threatening complications like severe hyperkalemia and malignant hyperthermia.

Eligibility Status	Affected Populations
Contraindicated	Patients with a personal or family history of Malignant Hyperthermia (MH) or skeletal muscle myopathies. Use is also prohibited after the acute phase of injury (post-24 hours) following major burns or multiple trauma, and in patients with known hypersensitivity to the drug.
Restricted Use	Pediatric patients are restricted; use is generally reserved for emergency intubation or urgent airway securing.
Special Caution	Patients with chronic renal impairment may receive a single dose if hyperkalemia is absent, but multiple doses should be avoided. Use during pregnancy is classified as Category C, permitted when the benefit outweighs risk. Excretion into human milk is unknown, but considered unlikely to affect the infant due to rapid metabolism.

---

Connection to the overall eligibility profile

Regulatory documents define eligibility based on high-risk factors that could lead to life-threatening complications. The profile contraindicates use in groups with genetic susceptibilities or conditions that raise hyperkalemia risk, while defining restricted use criteria for children and patients with certain organ or physiological limitations.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Дитилин (Succinylcholine) primarily through its potential for prolonged neuromuscular blockade and the risk of malignant hyperthermia.

Clinically Significant Interactions

Co-administration with Inhibitors of Plasma Cholinesterase—including certain organophosphates and anticholinesterase agents—can significantly enhance and prolong the paralytic effect of this medicine. This is due to reduced breakdown of the drug in the body, which requires careful clinical management.

Simultaneous use with volatile anesthetic agents (such as isoflurane or desflurane) is associated with an increased risk of triggering malignant hyperthermia in susceptible individuals, an interaction that mandates immediate discontinuation of the triggering agents and specific procedural steps.

Other Interactions

Other agents, including certain antibiotics (like aminoglycosides), antiarrhythmics (like quinidine or lidocaine), and magnesium salts, may also enhance the neuromuscular blocking action of Дитилин. Additionally, regulatory information notes that the risk of bradyarrhythmias may be reduced by pretreatment with anticholinergics such as atropine. Patients identified as poor metabolizers of plasma cholinesterase are at risk for prolonged effects, which may lead to avoidance of the drug in non-emergent settings.

The mechanism of action for Дитилин (Succinylcholine chloride) is defined by two precise mechanistic domains that govern its rapid onset and temporary, comprehensive physiological consequence on muscle activity.

---

Receptor Agonism and Neuromuscular Blockade

The primary mechanism involves the drug acting as an agonist (a chemical mimic) at the muscle-type Nicotinic Acetylcholine Receptor ( nAChR) on the motor endplate. This rapid binding and activation initiate a signaling sequence that causes the muscle membrane to enter a state of continuous depolarization (Phase I block). This sustained electrical activity then inactivates the adjacent voltage-gated sodium channels, making the muscle fiber completely unresponsive to subsequent nerve impulses. This cascading molecular event functionally suppresses all voluntary and involuntary skeletal muscle activity, leading immediately to flaccid paralysis.

---

⏳ Enzymatic Metabolism and Time-Limited Effect

The mechanism is uniquely constrained by its termination process. The duration of Дитилин's action is governed by its passive breakdown by the enzyme plasma pseudocholinesterase in the bloodstream. This rapid hydrolysis of the molecule terminates the effect at the receptor level. This process is the primary determinant of the drug's short physiological effect profile, but variability in enzyme activity (due to genetic factors) acts as a limitation, directly prolonging the resulting period of muscle paralysis.

Дитилин (succinylcholine chloride) is a highly specialized medication whose use is strictly governed by clinical protocols, focusing on precise administration in controlled medical settings.

Official Administration Guidelines

Administration Scope	Administration Details
Route of Administration	Primarily Intravenous (IV) injection or continuous infusion. The Intramuscular (IM) route is an alternative for situations where venous access is difficult, particularly in children.
Standard Adult Dosing	IV Initial Dose: Ranges from 0.3 mg/kg to 1.1 mg/kg of body weight; 0.6 mg/kg is a common dose for short procedures. IM Dose: 3 mg/kg to 4 mg/kg up to a maximum total of 150 mg.
Dosing Schedule	Administered as a single IV bolus for procedures lasting 4 to 6 minutes, or as a continuous IV infusion typically ranging from 2.5 mg/minute to 4.3 mg/minute for prolonged procedures.
Preparation Requirements	The solution must be visually inspected before use. It must be diluted (commonly to 1 mg/mL or 2 mg/mL) when preparing for continuous intravenous infusion.

Procedural and Population-Specific Rules

• Required Supervision: The drug must be administered only by or under the close supervision of experienced clinicians who are skilled in the management of artificial respiration and have immediate facilities for intubation.
• Consciousness State: To prevent patient distress, administration should occur after the induction of unconsciousness (adequate anesthesia), except in emergent, life-threatening situations.
• Pediatric Dosing: Use in pediatric patients is generally reserved for emergency intubation or when immediate securing of the airway is necessary. The standard IV dose is 2 mg/kg for infants and small children, and 1 mg/kg for older children.
• Monitoring: Neuromuscular function monitoring is recommended during continuous infusion to individualize the dosage and assess the depth of block.

Research Evidence / Overview of Studies for Дитилин

The research evidence for Дитилин (succinylcholine chloride) primarily focuses on its rapid and temporary action on muscle function. The available studies explored how quickly the medication starts and stops working, which is highly relevant in acute medical settings.

---

Evidence for Facilitating Tracheal Intubation

Research for this use involves Randomized Controlled Trials (RCTs) and large systematic reviews that combine data from many individual studies. These studies have primarily focused on short-term or episodic symptom patterns, relevant in trials assessing the immediate action needed for the procedure.

Researchers measured outcomes known as Intubating Conditions, including the degree of jaw relaxation. Findings indicate that the onset of measured paralysis occurred rapidly, typically within 60 seconds of injection, as measured in the observed populations. Studies report how symptoms evolved in the observed populations, including measurements of muscle activity change.

---

Evidence for Muscle Relaxation During Procedures

Research has examined the drug's role in providing temporary changes to muscle activity for short-duration medical interventions. Studies examined how quickly the total muscle block develops after injection and how quickly it reverses. Studies report that the duration of measured block for a single dose typically lasts only a few minutes, with the majority of patients experiencing a full return of measured muscle function within 5 to 10 minutes.

Research has not explored long-term maintenance of action, reflecting the drug’s intended ultra-short duration. Consequently, the research provides insight into short-term changes but offers limited data for scenarios that would require intermediate or prolonged change in muscle activity.

---

Research Gaps and Areas of Uncertainty

A significant research limitation is that the primary outcomes measured in studies are often surrogate endpoints (like intubating conditions) rather than patient-centered outcomes reflecting long-term health or safety. The research provides limited insight into how these immediate observed actions might translate into functional outcomes later on.

Furthermore, large-scale Randomized Controlled Trials are challenging to conduct in the most acutely ill, high-risk patients (e.g., those with severe trauma, burns). As a result, the data for these certain groups remain insufficient, and research is ongoing.

Key Studies & References

1. Impact of Succinylcholine vs. Rocuronium on Apnea Duration for Rapid Sequence Induction: A Prospective Cohort Study

Common questions about Дитилин (FAQ)

Q: What are the most commonly reported side effects of Дитилин?

A: According to official regulatory documents, the commonly reported effects include postoperative muscle pain (myalgia) and a short-lived muscle twitching known as fasciculations. These are documented as expected reactions related to how the drug works on muscle function.

Q: Why is the drug given only by injection and not orally?

A: Official prescribing information only authorizes the medicine for intravenous (IV) or intramuscular (IM) injection by a clinician. This administration route is necessary because the drug’s specialized purpose requires an ultra-short duration of action and an immediate, precise effect on the muscles.

Q: Can Дитилин be used during pregnancy or while breastfeeding?

A: Official information describes use during pregnancy as a risk-benefit determination made by the supervising physician, as it is classified as Pregnancy Category C. While excretion into human milk is unknown, official information indicates effects on the infant are considered unlikely due to the medicine's extremely rapid breakdown by the body.

Q: Is Дитилин used for purposes other than what is listed in the main section?

A: The medicine is officially indicated for use as an adjunct to general anesthesia and to facilitate tracheal intubation or skeletal muscle relaxation during medical procedures. Regulatory information states the drug may be used for other purposes, but those are specialized clinical determinations made by a healthcare provider.

Q: Does Дитилин cause fatigue or drowsiness?

A: The official safety profile for this medicine does not commonly list symptoms such as fatigue or drowsiness among the documented adverse reactions. This medicine is typically administered after the patient has already received general anesthesia to ensure unconsciousness.

Q: Is it normal to feel a mild sensation after starting Дитилин?

A: Yes, it is described in official documents that the medicine's action profile includes inducing fasciculations. This is a transient, brief muscle twitching or sensation that occurs just before the full onset of muscle relaxation.

Q: What should I do if I miss a dose of Дитилин?

A: This medicine is only administered by a healthcare professional as a part of a specialized procedure in a controlled medical setting. It is not a medication that is taken routinely at home, which means the general concept of a “missed dose” does not apply.

Q: Can Дитилин be taken if I have a history of heart issues?

A: Official safety documents warn of potential effects on the heart, including the risk of bradycardia (slow heart rate) and the severe risk of cardiac arrest linked to high potassium levels (hyperkalemia). Therefore, the medicine's use in patients with existing heart conditions requires specialized management by the administering clinician.

Q: Do studies suggest Дитилин is effective for long-term use?

A: Studies and official information indicate that research has not explored the medicine's use for long-term maintenance of action. The drug is designed only for ultra-short duration use, with effects lasting only a few minutes after a single dose.

Q: Is Дитилин considered safe for use in older adults?

A: Regulatory documents state that the use of this medicine in older adults requires careful dosage selection. This caution is due to the potential for age-related changes in organ functions, which are considered as part of the specialized dosage selection.

Q: Is the research evidence for Дитилин considered strong or still developing?

A: The research evidence for the drug's intended ultra-short-term action includes high-quality studies like Randomized Controlled Trials (RCTs) and systematic reviews. However, regulatory documents indicate that research has limited data concerning its use in high-risk patient groups, such as the acutely ill.

Q: Why is Дитилин sometimes given in a hospital setting?

A: Administration is restricted to ensure there is immediate access to the necessary equipment for artificial respiration and securing the patient’s airway. This necessity requires the medicine to be given by or under the close supervision of experienced clinicians.

Q: Does taking Дитилин affect my ability to drive or operate machinery?

A: The drug induces a brief but complete muscle paralysis that requires full recovery and monitoring following its administration in a clinical setting. Due to these effects, the full recovery period requires patients to avoid driving or operating machinery for a time determined by the supervising physician.

Q: Is it okay to use herbal supplements while taking Дитилин?

A: Official safety documents advise that clinicians be informed about all medicines and supplements being taken, including herbal or vitamin supplements. This is because certain agents, such as those containing magnesium salts, are noted to potentially enhance the drug’s neuromuscular blocking effect.

Q: Can Дитилин be crushed or split if a person has trouble swallowing pills?

A: No. The medicine is supplied only as a sterile solution for injection that must be administered intravenously or intramuscularly by trained medical personnel. It is not available in a tablet or pill form that can be swallowed, crushed, or split.

Q: What happens if Дитилин is stopped suddenly?

A: The drug’s action is naturally terminated by a rapid breakdown process in the bloodstream involving the enzyme plasma pseudocholinesterase. This physiological process determines the drug's ultra-short duration of action as opposed to the effect being stopped by a deliberate action.

Q: Can individuals with kidney problems use Дитилин?

A: Patients with chronic renal impairment may receive a single dose if the risk of elevated potassium levels (hyperkalemia) is absent. However, official information notes that multiple doses are typically avoided in these patients due to potential risks.

Q: What is the shelf life of Дитилин?

A: Official labeling defines the storage conditions and potency maintenance requirements for the medicine. The injection typically has a shelf life of 15 months when stored under refrigeration (2^circmathrmC to 8^circmathrmC).

Q: Is there any research looking at Дитилин use in specific genetic populations?

A: Regulatory information details that specific genetic factors are associated with the drug's safety and contraindications. For example, specific gene variants (RYR1 and CACNA1S) are known to increase the risk of triggering a severe reaction called malignant hyperthermia.

Q: What kind of monitoring is typically required while a person is on Дитилин?

A: Regulatory information specifies that neuromuscular function monitoring is recommended for patients who are receiving a continuous intravenous infusion of the medicine. This type of monitoring helps the clinician assess the depth of muscle blockade during the procedure.

Q: Is it possible for Дитилин to cause an allergic reaction?

A: Yes. Regulatory documents warn that severe, potentially life-threatening allergic reactions, including anaphylaxis, have been reported with this medicine and other similar neuromuscular blocking agents.

Q: How is Дитилин classified by major health regulatory bodies?

A: Дитилин is classified by regulatory bodies as a highly specialized, prescription-only (Rx) medication. The official package label includes a mandatory WARNING: Paralyzing Agent to emphasize its potent action and specialized use.

Q: Why is there a specific warning about certain pre-existing conditions and Дитилин use?

A: Warnings exist for certain pre-existing conditions, such as major burns or trauma, because the medicine's use in these patients may result in severe hyperkalemia (elevated potassium levels). This serious physiological reaction carries an explicit risk of cardiac arrest.

Q: Does Дитилин interact with birth control pills?

A: Regulatory interaction information notes that the medicine’s neuromuscular blocking effect may be increased or prolonged by the concomitant use of certain ingredients found in oral contraceptives (such as ethinyl estradiol).

Q: How soon after stopping Дитилин do the effects wear off completely?

A: Studies report that following a single dose, the full return of measured muscle function for the majority of patients typically occurs within 5 to 10 minutes. This ultra-short duration is a key characteristic of the medicine.

Q: Is there a recommended time of day for administering Дитилин?

A: The time of administration for this medicine is determined solely by the schedule of the medical procedure or emergency for which it is required. There is no specific time of day recommended for this drug outside of the clinical necessity.

Q: Why is Дитилин not recommended for children?

A: Use in children is generally reserved for urgent situations because the drug is associated with a rare but serious risk of acute muscle breakdown with severe hyperkalemia (high potassium). This reaction is linked to the risk of cardiac arrest in pediatric patients with certain undiagnosed muscle conditions.

Дитилин (Suxamethonium Chloride) injection requires specific storage conditions to maintain potency. The medication must typically be kept refrigerated at a temperature between 2mathrmC and 8mathrmC (36mathrmF and 46mathrmF). It is crucial to protect the vials or ampoules from light and to not allow the solution to freeze. Freezing can lead to degradation and loss of efficacy.

Once prepared or opened, the solution should generally be used immediately, and any unused portion must be discarded safely. Due to its classification as a potent medication, disposal should never occur via wastewater or household trash. All unused or expired Дитилин and related waste materials must be disposed of in accordance with hospital or local hazardous waste regulations to ensure proper environmental and safety protocols are followed.